Serum proteins as tumour markers for breast cancer

Mattison, Parnell C.; Cove, D.H.; Walsh, Linda; Howell, Anthony; McConkey, B; Morrison, J. M.

doi:10.1038/bjc.1981.78

Cited by 8 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive relation between several inflammatory proteins and breast cancer prognosis, tumor burden, and metastasis, studied since the 1980s, has emerged as a clinical marker (Mattison et al, 1981;Mortensen & Rudczynski, 1982). Serum CRP levels and lymphoid infiltrates in breast carcinoma positively correlate (Mortensen & Rudczynski, 1982).…”

Section: Breast Development and Physiologymentioning

confidence: 99%

Chronic Inflammation and Breast Pathology: A Theoretical Model

Lithgow

Covington

2005

Biological Research For Nursing

View full text Add to dashboard Cite

Breast cell pathology results from biochemical and molecular changes that culminate in the cell's loss of functional responsiveness. The epithelial cell compartment in the breast ductal system is the site of approximately 98% of malignant proliferations, and it is from within these cells that the first biochemical signal of change may be expressed as an inflammatory response. Inflammation may be represented by biomarkers of early pathologic changes in breast cells and be associated with risk for the development of breast cancer. A theoretical model of the inflammatory process is proposed showing predictive linkages among stimuli in the breast microenvironment and the development of breast pathology, in particular, breast cancer. This model fuels intervention concepts that may prevent malignant breast health outcomes.

show abstract

Section: Breast Development and Physiologymentioning

confidence: 99%

Chronic Inflammation and Breast Pathology: A Theoretical Model

Lithgow

Covington

2005

Biological Research For Nursing

View full text Add to dashboard Cite

show abstract

Glycosylated haemoglobin levels in breast cancer patients receiving cytotoxic chemotherapy

Cantwell

Shirley

Fennelly

1981

Breast Cancer Res Tr

View full text Add to dashboard Cite

Factors influencing the acute phase protein levels in patients with esophageal cancer

Saito

Kuwahara

Shimoda

et al. 1991

The Japanese Journal of Surgery

View full text Add to dashboard Cite

Based on the findings that the enhancement of serum alpha 2-macroglobulin (A2M) is associated with the occurrence of infectious complications following surgery in patients with esophageal cancer, we examined possible factors which could contribute to the alterations of serum acute phase protein levels in patients with this disease. A multiple linear regression analysis was made for 71 patients with esophageal cancer and 58 with gastric cancer. In patients with esophageal cancer, protein calorie malnutrition (PCM) and age factors more strongly contributed to the alteration of 6 acute phase protein levels than did the malignant tumor when compared to those with gastric acner. PCM was negatively associated with A2M levels while it was positively associated with alpha 1-acidglycoprotein (A1AG) and haptoglobin (Hp) levels. Age did not contribute to the A2M levels but did have a negative effect on the Hp, ceruloplasmin (Cp) and fibronectin (Fn) levels. On the other hand, the malignant tumor was positively related only to the A1AG levels. Since none of these factors contributed to the elevation of A2M levels, it is suggested that the presence of chronic infection might be a factor contributing to the A2M increase which was associated with the occurrence of postoperative infectious complications in patients with this disease.

show abstract

Serum proteins as tumour markers for breast cancer

Cited by 8 publications

References 17 publications

Chronic Inflammation and Breast Pathology: A Theoretical Model

Chronic Inflammation and Breast Pathology: A Theoretical Model

Glycosylated haemoglobin levels in breast cancer patients receiving cytotoxic chemotherapy

Factors influencing the acute phase protein levels in patients with esophageal cancer

Contact Info

Product

Resources

About